Recommendations from the EGAPP Working Group: Testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors

Genetics in Medicine

Volumn 9, Issue 12, 2007, Pages 819-825

  Berg, Alfred O ^a   Piper, Margaret ^b   Armstrong, Katrina ^c   Botkin, Jeffrey ^d   Calonge, Ned ^e   Haddow, James ^f   Hayes, Maxine ^g   Kaye, Celia ^h   Phillips, Kathryn A ⁱ   Richards, Carolyn Sue ^j   Scott, Joan A ^k   Strickland, Ora L ^l   Teutsch, Steven ^m  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Blue Cross and Blue Shield Association   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e Colorado Department of Public Health and Environment ^*  (United States)

^f Women and Infants' Hospital   (United States)

^g WASHINGTON STATE DEPARTMENT OF HEALTH   (United States)

^h UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^k JOHNS HOPKINS UNIVERSITY   (United States)

^l EMORY UNIVERSITY   (United States)

^m MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

CYP450; Depression; P450; Pharmacogenomic; SSRI

Indexed keywords

CITALOPRAM; CYTOCHROME P450; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

DEPRESSION; DISEASE ASSOCIATION; EVIDENCE BASED MEDICINE; GENE DELETION; GENE DUPLICATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; NAUSEA; REVIEW; STATISTICAL SIGNIFICANCE;

ADULT; CYTOCHROME P-450 ENZYME SYSTEM; DEPRESSION; GENETIC SCREENING; HUMANS; POLYMORPHISM, GENETIC; SEROTONIN UPTAKE INHIBITORS;

EID: 37349093041     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e31815bf9a3     Document Type: Review

References (54)

1. Matchar DB, Thakur ME, Grossman I, McCrory DC, et al. Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Evidence Report/Technology Assessment No. 146. (Prepared by the Duke Evidence-based Practice Center under Contract No. 290-02-0025.) AHRQ Publication No. 07-E002. Rockville, MD: Agency for Healthcare Research and Quality. http://www.ahrq.gov/downloads/pub/evidence/ pdf/cyp450/cyp450.pdf. Accessed January 23, 2007.
2. Piper, MA. Blue Cross and Blue Shield Special Report: Genotyping for cytochrome P450 polymorphisms to determine drug-metabolizer status. www.bcbs.com/tec/Vol19/19_09.pdf. Accessed July 6, 2006. (No longer posted on TEC website due to age of report; copy available on request).
3. US Food and Drug Administration 510(k) Substantial Equivalence Determination Decision Summary for Roche AmpliChip CYP450 microarray for identifying CYP2D6 genotype (510(k) Number k042259). http://www.fda.gov/cdrh/ reviews/k042259.pdf. Accessed April 19, 2006.
4. US Food and Drug Administration 510(k) Substantial Equivalence Determination Decision Summary for Roche AmpliChip CYP450 microarray for identifying CYP2C19 genotype (510(k) Number k043576). www.fda.gov/cdrh/reviews/ k043576.pdf. Accessed April 19, 2006.
5. Broly F, Marez D, Lo Guidice JM, Sabbagh N, et al. A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency. Hum Genet 1995;96:601-603.
6. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, et al. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995;274:516-520.
7. Daly AK, Leathart JB, London SJ, Idle JR. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution. Hum Genet 1995;95:337-341.
8. Evert B, Griese EU, Eichelbaum M. Cloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon. Pharmacogenetics 1994;4:271-274.
9. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, et al. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991;48:943-950.
10. Gough AC, Miles JS, Spurr NK, Moss JE, et al. Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 1990;347:773-776.
11. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998;8:15-26.
12. Hanioka N, Kimura S, Meyer UA, Gonzalez FJ. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet 1990;47:994-1001.
13. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A 1993;90:11825-11829.
14. Kagimoto M, Heim M, Kagimoto K, Zeugin T, et al. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 1990;265:17209-17214.
15. Lovlie R, Daly AK, Idle JR, Steen VM. Characterization of the 16+9 kb and 30+9 kb CYP2D6 XbaI haplotypes. Pharmacogenetics 1997;7:149-152.
16. Marez D, Sabbagh N, Legrand M, Lo-Guidice JM, et al. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Pharmacogenetics 1995;5:305-311.
17. Marez-Allorge D, Ellis SW, Lo Guidice JM, Tucker GT, et al. A rare G2061 insertion affecting the open reading frame of CYP2D6 and responsible for the poor metabolizer phenotype. Pharmacogenetics 1999;9:393-396.
18. Masimirembwa C, Persson I, Bertilsson L, Hasler J, et al. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996;42:713-719.
19. Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol Pharmacol 1997;52:1034-1040.
20. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997;60:284-295.
21. Steen VM, Molven A, Aarskog NK, Gulbrandsen AK. Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. Hum Mol Genet 1995;4:2251-2257.
22. Saxena R, Shaw GL, Relling MV, Frame JN, et al. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 1994;3:923-926.
23. Neville CF, Ninomiya S, Shimada N, Kamataki T, et al. Characterization of specific cytochrome P450 enzymes responsible for the metabolism of diazepam in hepatic microsomes of adult male rats. Biochem Pharmacol 1993;45:59-65.
24. Eriksson S, Berg LM, Wadelius M, Alderborn A. Cytochrome p450 genotyping by multiplexed real-time DNA sequencing with pyrosequencing technology. Assay Drug Dev Technol 2002;1:49-59.
25. Hersberger M, Marti-Jaun J, Rentsch K, Hanseler E. Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 2000;46:1072-1077.
26. Muller B, Zopf K, Bachofer J, Steimer W. Optimized strategy for rapid cytochrome P450 2D6 genotyping by real-time long PCR. Clin Chem 2003;49:1624-1631.
27. Schaeffeler E, Schwab M, Eichelbaum M, Zanger UM. CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR. Hum Mutat 2003;22:476-485.
28. Soderback E, Zackrisson AL, Lindblom B, Alderborn A. Determination of CYP2D6 gene copy number by pyrosequencing. Clin Chem 2005;51:522-531.
29. Stamer UM, Bayerer B, Wolf S, Hoeft A, et al. Rapid and reliable method for cytochrome P450 2D6 genotyping. Clin Chem 2002;48:1412-1417.
30. Chou WH, Yan FX, Robbins-Weilert DK, Ryder TB, et al. Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 2003;49:542-551.
31. Mizugaki M, Hiratsuka M, Agatsuma Y, Matsubara Y, et al. Rapid detection of CYP2C18 genotypes by real-time fluorescence polymerase chain reaction. J Pharm Pharmacol 2000;52:199-205.
32. Liu ZQ, Cheng ZN, Huang SL, Chen XP, et al. Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. Br J Clin Pharmacol 2001;52:96-99.
33. Wang JH, Liu ZQ, Wang W, Chen XP, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001;70:42-47.
34. Yoon YR, Cha IJ, Shon JH, Kim KA, et al. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. Clin Pharmacol Ther 2000;67:567-576.
35. Yu BN, Chen GL, He N, Ouyang DS, et al. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. Drug Metab Dispos 2003;31:1255-1259.
36. Ozdemir V, Tyndale RF, Reed K, Herrmann N, et al. Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. J Clin Psychopharmacol 1999;19:472-475.
37. Berle JO, Steen VM, Aamo TO, Breilid H, et al. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. J Clin Psychiatry 2004;65:1228-1234.
38. Charlier C, Broly F, Lhermitte M, Pinto E, et al. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit 2003;25:738-742.
39. Eap CB, Bondolfi G, Zullino D, Savary-Cosendai L, et al. Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers. J Clin Psychopharmacol 2001;21:330-334.
40. Grasmader K, Verwohlt PL, Rietschel M, Dragicevic A, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004;60:329-336.
41. LLerena A, Dorado P, Berecz R, Gonzalez AP, et al. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steadystate conditions. Eur J Clin Pharmacol 2004;59:869-873.
42. Murphy GM Jr, Kremer C, Rodrigues HE, Schatzberg AF. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003;160:1830-1835.
43. Ohara K, Tanabu S, Ishibashi K, Ikemoto K, et al. CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects. Eur J Clin Pharmacol 2003;58:659-661.
44. Sawamura K, Suzuki Y, Someya T. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine. Eur J Clin Pharmacol 2004;60:553-557.
45. Stedman CA, Begg EJ, Kennedy MA, Roberts R, et al. Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Hum Psychopharmacol 2002;17:187-190.
46. Scordo MG, Spina E, Dahl ML, Gatti G, et al. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol 2005;97:296-301.
47. Ueda M, Hirokane G, Morita S, Okawa M, et al. The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:486-491.
48. Gerstenberg G, Aoshima T, Fukasawa T, Yoshida K, et al. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology (Berl) 2003;167:443-448.
49. Rau T, Wohlleben G, Wuttke H, Thuerauf N, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 2004;75:386-393.
50. Kawanishi C, Lundgren S, Agren H, Bertilsson L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 2004;59:803-807.
51. Allgulander C, Nilsson B. A prospective study of 86 new patients with social anxiety disorder. Acta Psychiatr Scand 2001;103:447-452.
52. Roberts RL, Mulder RT, Joyce PR, Luty SE, et al. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol 2004;19:17-23.
53. Suzuki Y, Sawamura K, Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients. Neuropsychopharmacology 2006;31:825-831.
54. Chen S, Chou WH, Blouin RA, Mao Z, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996;60:522-534.